Sarepta Therapeutics Logo
US8036071004
A1J1BH
SRPT

Sarepta Therapeutics

Previsión

El precio objetivo medio de los analistas es de 19,50 € (+60,36 %). La mediana es de 18,23 € (+49,92 %).

Comprar
  31
Mantener
  18
Vender
  6

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Sarepta presents pipeline data and expects gradual recovery for ELEVIDYS

    At the Morgan Stanley Healthcare Conference, Sarepta emphasized that marketed products generate cash flow while the siRNA pipeline supports long‑term growth. CEO Michael Severino noted early signs of stabilization after the safety‑related issues with ELEVIDYS, but expects meaningful commercial improvement only in 2027. Key near‑term catalysts are data from the multiple‑ascending‑dose studies of SRP‑1001 (FSHD) and SRP‑1003 (DM1) in the second half of 2026 and higher dose cohorts in early 2027; the PMO franchise remains robust with high treatment adherence. » Más en de.investing.com


  • Sarepta Therapeutics appoints Michael Severino as CEO – shares rise in premarket trading

    Sarepta Therapeutics named Dr. Michael Severino as its new CEO effective July 28, 2026; Doug Ingram is stepping down and will remain in an advisory role through the end of 2026. The stock rose about 5.2% in premarket trading, driven by confidence in Severino’s experience at Tessera Therapeutics and AbbVie. Analysts warn of a challenging competitive landscape in Duchenne muscular dystrophy; attention also turns to the expected Q2 results on August 5. The share price was $16.49, well below the 52-week high of $25.32 but recovered from a low of $11.68. » Más en de.investing.com


  • Sarepta Therapeutics rises after FDA acceptance of sNDA for AMONDYS 45 and VYONDYS 53

    The FDA has accepted the supplemental new drug applications (sNDAs) for AMONDYS 45 (Casimersen) and VYONDYS 53 (Golodirsen) for review and set a PDUFA date of February 28, 2027. The filings rely on the phase-3 ESSENCE study, which did not meet its primary endpoint but showed numerical trends and post‑hoc analyses favoring treatment. The news triggered a share gain of about 6.1% and was supported by Mizuho’s maintained 'Outperform' rating with a $31 price target and a favorable market backdrop. Full approval would remove substantial regulatory uncertainty for the PMO portfolio; the PMO franchise reported net product revenue of $228.6 million in Q1 2026. » Más en de.investing.com


  • Sarepta Therapeutics stock falls after steep drop in Elevidys sales

    Sarepta Therapeutics reported first-quarter Elevidys sales of $102 million versus $375 million in the year-ago quarter, driven by a restricted approval for ambulatory patients following FDA safety reviews. Total revenue was $730.8 million, down $14.1 million, partly offset by higher collaboration revenue. The stock fell about 10.3% in premarket trading to $122.96. » Más en de.investing.com


  • Sarepta returns to profitability in Q1 2026 despite commercial realignment

    Sarepta reported a non-GAAP earnings per share of $3.16 for Q1 2026 on revenue of $731 million, significantly beating expectations. The company swung to operating profitability thanks to disciplined cost management and a favorable revenue mix, with collaboration revenues (including $325 million from Roche) making up a large portion of results. ELEVIDYS generated $102 million in sales, PMO products contributed $229 million, and cash and cash equivalents stood at $748 million. Sarepta reaffirmed its 2026 guidance (net product revenue $1.2–1.4 billion) and emphasized that pipeline progress and balance-sheet developments make external capital unnecessary for the time being. » Más en de.investing.com

En 2022, Sarepta Therapeutics ya ha pagado 0,26 € en dividendos. El último pago fue en marzo de 2022.

Datos financieros

En el último trimestre, Sarepta Therapeutics tuvo unos ingresos de 336,68 M € y un beneficio neto de -25,13 M €

(EUR) septiembre de 2026
YoY
Ingresos 336,68 M 1,07 %
Beneficio bruto 170,25 M 19,63 %
Beneficio neto -25,13 M 83,61 %
EBITDA 1,54 M 101,08 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
1302,73 M €
Número de acciones
107,24 M
Máximo/mínimo de 52 semanas
22,49 € - 12,08 €
Dividendos No
Beta
0,21
Ratio P/E
148,11
Ratio PEG
0,30
Ratio P/B
0,92
Ratio P/S
0,73

Perfil de la empresa

Sarepta Therapeutics, Inc., una empresa biofarmacéutica en fase comercial, se centra en el descubrimiento y desarrollo de terapias dirigidas al ARN, terapias génicas y otras modalidades terapéuticas genéticas para el tratamiento de enfermedades raras. Ofrece EXONDYS 51 inyectable para tratar la distrofia muscular de Duchenne (Duchenne) en pacientes con una mutación confirmada del gen de la distrofina que es susceptible de salto del exón 51; y VYONDYS 53 para el tratamiento de Duchenne en pacientes con una mutación confirmada del gen de la distrofina que es susceptible de salto del exón 53. La compañía también está desarrollando AMONDYS 45, un candidato a producto que utiliza la química de oligómeros morfolinos de fosforodiamidato y la tecnología de salto de exones para saltar el exón 45 del gen de la distrofina; SRP-5051, un PMO conjugado con péptidos que se une al exón 51 del pre-ARNm de la distrofina; SRP-9001, un programa de terapia génica con microdistrofina para DMD; y SRP-9003, un programa de terapia génica para distrofias musculares de cinturón de extremidades. Tiene acuerdos de colaboración con F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; y StrideBio. La compañía fue constituida en 1980 y tiene su sede en Cambridge, Massachusetts.

Nombre
Sarepta Therapeutics
CEO
Michael E. Severino
Sede Cambridge, ma
Estados Unidos
Sitio web
Sector
Salud
Industria
Biotecnología
Salida a bolsa
04/06/1997
Empleados 835

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
SRPT
London Stock Exchange
0L35.L
Frankfurt
AB3A.F
Düsseldorf
AB3A.DU
London
0L35.L
SIX
AB3A.SW
München
AB3A.MU
Hamburg
AB3A.HM
Milan
1SRPT.MI
🍪

Parqet  usa cookies. Más información